Loading
A phase 2 trial of AK117 in triple-negative breast cancer, run by Akeso, active and no longer recruiting.
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05227664 by Akeso, with 120 participants enrolled, started 2022-03-23 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK117, AK112, Nab paclitaxel and paclitaxel.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.